Basic Information
| LncRNA/CircRNA Name | UCA1 |
| Synonyms | UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36 |
| Region | GRCh38_19:15828206-15836326 |
| Ensemble | ENSG00000214049 |
| Refseq | NR_015379 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR etc. |
| Sample | urine |
| Expression Pattern | up-regulated |
| Function Description | Compared to control groups, the malignant group had higher expression levels of miR-210, miR-96, and lncRNA-UCA1.The urinary expression of HYAL1 protein and its epigenetic regulators were higher in BC patients (P<.001).The receiver-operating characteristic curve analyses demonstrated that each one had good sensitivity and specificity for distinguishing BC patients from non-BC ones (HYAL1, 89.4 and 91.2 %; miR-210, 76.6 and 93 %; miR-96, 76.6 and 89.4 %; and lncRNA-UCA1, 91.5 and 96.5 %). There was a significant positive correlation between HYAL1 and the selected epigenetic biomarkers. |
| Pubmed ID | 26138586 |
| Year | 2015 |
| Title | Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis. |
External Links
| Links for UCA1 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |